Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jun 7, 2022
Open Peer Review Period: Jun 7, 2022 - Aug 2, 2022
Date Accepted: Jan 5, 2023
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effect of prophylactic intravenous amiodarone administration on reperfusion ventricular fibrillation after release of aortic cross-clamp in patients with left ventricular hypertrophy undergoing cardiopulmonary bypass surgery: study protocol for a double-blind randomized controlled trial.
ABSTRACT
Background:
Ventricular fibrillation (VF) is a common arrhythmia occurred after the release of aortic cross-clamp (ACC) in patients undergoing cardiopulmonary bypass (CPB) surgery. Repeated defibrillation and long duration of VF could increase myocardial injuries. In patients with left ventricular hypertrophy (LVH), VF is easier to occur and more difficult to be terminated. Amiodarone, known as class III antiarrhythmic agent, has the prominent properties of converting VF and restoring the sinus rhythm. Before ACC release, administration of amiodarone has been confirmed useful to reduce occurrence of VF. However, few studies focused on the effect of amiodarone before ACC release on reducing VF in patients with LVH.
Objective:
This study concentrates on the efficacy of prophylactic intravenous amiodarone administration on reperfusion VF after release of ACC in patients with LVH undergoing CPB surgery.
Methods:
This will be a prospective, randomized, double-blind, placebo-controlled trial. The trial is to enroll 54 patients with LVH aged 18 to 75 years who will undergo CPB surgery. All eligible participants will be randomly allocated to either the amiodarone or placebo group by using the block randomization in a 1:1 ratio. The primary endpoint will be the incidence rate of VF 30 minutes after ACC release and be assessed using the Chi-square test. All data will be analyzed in accordance with the intention-to-treat principle.
Results:
This study has been approved by the Institutional Ethics Committee of the First Affiliated Hospital of Nanjing Medical University. This clinical trial protocol was developed based on the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 Statement.
Conclusions:
With this trial, we are hoping to demonstrate that prophylactic infusion of amiodarone before ACC release could reduce the occurrence of reperfusion VF in LVH patients. Clinical Trial: This study was registered on Chinese Clinical Trial Registry (http://www.chictr.org.cn/) with the ID ChiCTR2000035057
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.